Case of neuro-Behcet's disease successfully maintained a remission using infliximab for 2 years

被引：8

作者：

Kanemaru, Hisashi ^{[1
]}

Makino, Takamitsu ^{[1
]}

Jinnin, Masatoshi ^{[1
]}

Yonemitsu, Aya ^{[1
]}

Makino, Katsunari ^{[1
]}

Ihn, Hironobu ^{[1
]}

机构：

[1] Kumamoto Univ, Fac Life Sci, Dept Dermatol & Plast Surg, Kumamoto 8608556, Japan

来源：

JOURNAL OF DERMATOLOGY | 2013年 / 40卷 / 08期

关键词：

Behcet's disease; infliximab; long-term effects; neuro-Behcet's disease; tumor necrosis factor-; ALPHA; IL-8;

D O I：

10.1111/1346-8138.12203

中图分类号：

R75 [皮肤病学与性病学];

学科分类号：

100206 ;

摘要：

Behcet's disease is a systemic inflammatory disorder with chronic remissions and relapses. Involvement of the central nervous system, called neuro-Behcet's disease (NBD), is a serious complication. Although corticosteroids and immunosuppressive agents are used, there is no definite standard of treatment with long term-effects for NBD. Here, we report a female case with NBD successfully treated by infliximab and corticosteroids for 2years. Our report suggests treatment with infliximab may be effective for long-term remission of NBD.

引用

页码：632 / 634

页数：3

共 12 条

[1] Infliximab for patients with neuro-Behcet's disease: case series and literature review [J].

Borhani Haghighi, Afshin ;

Safari, Anahid ;

Nazarinia, Mohammad Ali ;

Habibagahi, Zahra ;

Shenavandeh, Saeedeh .

CLINICAL RHEUMATOLOGY, 2011, 30 (07) :1007-1012

[2] Serum levels of TNF-α, sIL-2R, IL-6, and IL-8 are increased and associated with elevated lipid peroxidation in patients with Behcet's disease [J].

Evereklioglu, C ;

Er, H ;

Türköz, Y ;

Çekmen, M .

MEDIATORS OF INFLAMMATION, 2002, 11 (02) :87-93

[3] Infliximab monotherapy in Neuro-Behcet's disease: Four year follow-up in a long-standing case resistant to conventional therapies [J].

Fasano, Alfonso ;

D'Agostino, Magda ;

Caldarola, Giacomo ;

Feliciani, Claudio ;

De Simone, Clara .

JOURNAL OF NEUROIMMUNOLOGY, 2011, 239 (1-2) :105-107

[4]

Gül A, 2001, CLIN EXP RHEUMATOL, V19, pS6

[5] EULAR recommendations for the management of Behcet disease [J].

Hatemi, G. ;

Silman, A. ;

Bang, D. ;

Bodaghi, B. ;

Chamberlain, A. M. ;

Gul, A. ;

Houman, M. H. ;

Kotter, I. ;

Olivieri, I. ;

Salvarani, C. ;

Sfikakis, P. P. ;

Siva, A. ;

Stanford, M. R. ;

Stuebiger, N. ;

Yurdakul, S. ;

Yazici, H. .

ANNALS OF THE RHEUMATIC DISEASES, 2008, 67 (12) :1656-1662

[6] Central nervous system symptoms in patients with Behcet disease receiving cyclosporine therapy [J].

Kotake, S ;

Higashi, K ;

Yoshikawa, K ;

Sasamoto, Y ;

Okamoto, T ;

Matsuda, H .

OPHTHALMOLOGY, 1999, 106 (03) :586-589

[7]

MEGE JL, 1993, J RHEUMATOL, V20, P1544

[8] Infliximab for the treatment of neuro-Behcet's disease: A case series and review of the literature [J].

Pipitone, Nicolo ;

Olivieri, Ignazio ;

Padula, Angela ;

D'Angelo, Salvatore ;

Nigro, Angelo ;

Zuccoli, Giulio ;

Boiardi, Luigi ;

Salvarani, Carlo .

ARTHRITIS & RHEUMATISM-ARTHRITIS CARE & RESEARCH, 2008, 59 (02) :285-290

[9] Infliximab for recurrent, sight-threatening ocular inflammation in Adamantiades-Behcet disease [J].

Sfikakis, PP ;

Kaklamanis, PH ;

Elezoglou, A ;

Katsilambros, N ;

Theodossiadis, PG ;

Papaefthimiou, S ;

Markomichelakis, N .

ANNALS OF INTERNAL MEDICINE, 2004, 140 (05) :404-406

[10] Behcet's disease: a new target for anti-tumour necrosis factor treatment [J].

Sfikakis, PP .

ANNALS OF THE RHEUMATIC DISEASES, 2002, 61 :51-53

← 1 2 →